Ian K Lee, DO
Critical Care (Intensivists) · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Hospitals listed: Kaiser Foundation Hospital-San Jose. That is not proof they admit you there this week.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lee’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Kaiser Foundation Hospital-San JoseSan Jose, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Kaiser Permanente, which runs 41 hospitals in 3 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.258, Oct 2024 – Sep 2025
See every measure and the patient survey for Kaiser Foundation Hospital-San Jose
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.258 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.22 to 2.37) · 181 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.43 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 271 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 2,952 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.04 to 0.5) · 894 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 908 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.19 (0.67 to 5.72) · 176 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 61 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.23 (0.53 to 3.92) · 168 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.11 (0 to 17.58) · 68 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.85 (0.67 to 9.03) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.43 (0 to 1.53) · 630 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 48 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.843 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.88 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.611 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 171 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 571 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 147.1 · 28 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 21 · 639 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 48 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 157 cases | None | Jul 2023 – Jun 2025 |
What patients said (1,294 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 61% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$1,763
Medicare paid this office $1,763 for 13 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
13 Original Medicare patients in 2024. Average age 75 · Under 65 0% · Health risk score 1.87. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
The office billed $5,948, Medicare allowed $2,317 and paid $1,763; for 23 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 13 | 23 | 75 | 1.87 | $5,948 | $1,763 |
| 2023 | 17 | 23 | 78 | 2.56 | $4,626 | $1,968 |
| 2022 | 19 | 37 | 72 | 2.20 | $5,643 | $2,245 |
| 2021 | 18 | 39 | 71 | 2.56 | $6,470 | $2,493 |
| 2020 | 25 | 46 | 72 | 2.83 | $7,858 | $3,348 |
| 2019 | 14 | 20 | 72 | 3.14 | $4,410 | $1,435 |
| 2018 | 17 | 70 | 68 | 3.25 | $13,440 | $4,581 |
| 2017 | 23 | 45 | 71 | 3.29 | $9,119 | $3,001 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2021: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,757 | $65 |
2020: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,002 | $67 |
2018: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $3,485 | $61 |
2017: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,336 | $61 |
Medicaid work
$0 in 2022
Medicaid paid $0 for 14 billed services this clinician did in 2022, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time | 14 | $0 |
| 2022 | 14 | 1 | 14 | $0 |
Drugs they prescribed that Part D paid
$173,928
Pharmacies billed $173,928 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (14 of 435) in 2024. A higher opioid share than 9 in 10 peers; the typical critical care (intensivists) clinician is at 0%. Long-acting opioids: 100% of their opioid prescriptions.
257 generic and 178 brand-name prescriptions · $173,928 in drug cost · 51 antibiotic prescriptions to 29 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Spiriva Respimat | 39 | $25,899 | $664 |
| Trelegy Ellipta | 18 | $21,596 | $1,200 |
| Stiolto Respimat | 17 | $15,492 | $911 |
| Breyna | 30 | $4,385 | $146 |
| Pirfenidone | 14 | $3,495 | $250 |
See all 13 drugs
| Spiriva Respimat | 39 | $25,899 | $664 |
| Trelegy Ellipta | 18 | $21,596 | $1,200 |
| Stiolto Respimat | 17 | $15,492 | $911 |
| Breyna | 30 | $4,385 | $146 |
| Pirfenidone | 14 | $3,495 | $250 |
| Mycophenolate Mofetil | 14 | $3,074 | $220 |
| Roflumilast | 18 | $2,254 | $125 |
| Levalbuterol Tartrate Hfa | 20 | $1,467 | $73 |
| Albuterol Sulfate Hfa | 31 | $844 | $27 |
| Azithromycin | 33 | $558 | $17 |
| Prednisone | 34 | $354 | $10 |
| Methadone | 14 | $236 | $17 |
| Pantoprazole | 15 | $144 | $10 |
Year by year
| 2024 | 435 | 129 | 3% (14) | 41% | $173,928 |
| 2023 | 399 | 121 | None | 52% | $175,028 |
| 2022 | 417 | 125 | 0% (0) | 56% | $260,444 |
| 2021 | 357 | 111 | None | 54% | $226,663 |
| 2020 | 385 | 120 | 0% (0) | 70% | $220,302 |
| 2019 | 411 | 158 | None | 67% | $176,400 |
| 2018 | 397 | 129 | None | 54% | $155,931 |
| 2017 | 347 | 109 | 0% (0) | 51% | $50,168 |
| 2016 | 78 | 35 | 22% (17) | 49% | $7,869 |
| 2015 | 34 | 13 | None | 62% | $6,394 |
| 2014 | 23 | None | 0% (0) | None | $2,779 |
| 2013 | 22 | None | 0% (0) | None | $449 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Spiriva Respimat | 55 | $33,381 | $607 |
| Symbicort | 53 | $17,296 | $326 |
| Pirfenidone | 16 | $7,814 | $488 |
| Roflumilast | 13 | $2,911 | $224 |
| Mycophenolate Mofetil | 15 | $2,061 | $137 |
| Levalbuterol Tartrate Hfa | 30 | $2,036 | $68 |
| Alvesco | 16 | $1,972 | $123 |
| Prednisone | 26 | $405 | $16 |
| Amoxicillin-Clavulanate Potass | 13 | $395 | $30 |
| Azithromycin | 25 | $352 | $14 |
| Albuterol Sulfate Hfa | 12 | $235 | $20 |
2022: 9 drugs
| Spiriva Respimat | 78 | $45,201 | $579 |
| Symbicort | 65 | $19,866 | $306 |
| Pirfenidone | 11 | $15,155 | $1,378 |
| Wixela Inhub | 21 | $6,571 | $313 |
| Levalbuterol Tartrate Hfa | 21 | $1,503 | $72 |
| Mycophenolate Mofetil | 13 | $1,338 | $103 |
| Prednisone | 28 | $437 | $16 |
| Albuterol Sulfate Hfa | 20 | $382 | $19 |
| Azithromycin | 17 | $304 | $18 |
2021: 9 drugs
| Esbriet | 12 | $124,424 | $10,369 |
| Spiriva Respimat | 43 | $30,267 | $704 |
| Advair Hfa | 26 | $11,926 | $459 |
| Wixela Inhub | 42 | $9,685 | $231 |
| Stiolto Respimat | 15 | $6,025 | $402 |
| Mycophenolate Mofetil | 17 | $3,427 | $202 |
| Alvesco | 15 | $2,303 | $154 |
| Albuterol Sulfate Hfa | 30 | $557 | $19 |
| Prednisone | 17 | $289 | $17 |
2020: 9 drugs
| Esbriet | 11 | $118,284 | $10,753 |
| Spiriva Respimat | 53 | $31,302 | $591 |
| Stiolto Respimat | 30 | $16,116 | $537 |
| Advair Hfa | 28 | $14,180 | $506 |
| Advair Diskus | 52 | $10,931 | $210 |
| Alvesco | 28 | $3,310 | $118 |
| Ventolin Hfa | 33 | $1,935 | $59 |
| Prednisone | 25 | $466 | $19 |
| Azithromycin | 13 | $145 | $11 |
2019: 10 drugs
| Spiriva Respimat | 60 | $27,447 | $457 |
| Stiolto Respimat | 33 | $20,826 | $631 |
| Advair Diskus | 70 | $18,393 | $263 |
| Advair Hfa | 24 | $14,986 | $624 |
| Ventolin Hfa | 41 | $3,693 | $90 |
| Mycophenolate Mofetil | 11 | $2,354 | $214 |
| Alvesco | 16 | $1,994 | $125 |
| Amoxicillin-Clavulanate Potass | 16 | $386 | $24 |
| Prednisone | 11 | $306 | $28 |
| Azithromycin | 16 | $292 | $18 |
2018: 8 drugs
| Advair Diskus | 69 | $17,933 | $260 |
| Spiriva Respimat | 27 | $13,929 | $516 |
| Ventolin Hfa | 45 | $2,567 | $57 |
| Rifampin | 14 | $1,477 | $105 |
| Ethambutol | 13 | $1,433 | $110 |
| Qvar | 13 | $1,298 | $100 |
| Prednisone | 26 | $846 | $33 |
| Azithromycin | 15 | $525 | $35 |
2017: 11 drugs
| Spiriva Respimat | 40 | $12,926 | $323 |
| Dulera | 29 | $7,633 | $263 |
| Advair Diskus | 18 | $4,775 | $265 |
| Ventolin Hfa | 34 | $1,746 | $51 |
| Qvar | 20 | $1,600 | $80 |
| Rifampin | 13 | $1,526 | $117 |
| Ethambutol | 11 | $900 | $82 |
| Prednisone | 30 | $861 | $29 |
| Azithromycin | 12 | $456 | $38 |
| Doxycycline Monohydrate | 15 | $290 | $19 |
| Fluticasone Propionate | 12 | $157 | $13 |
2016: 1 drug
| Methadone | 17 | $245 | $14 |
Money from drug and device companies
$141 in 2025
| 2025 | 1 | 1 | None | $141 |
| 2024 | 2 | 4 | None | $191 |
| 2023 | 1 | 2 | None | $222 |
| 2022 | 1 | 1 | None | $45 |
| 2019 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biogen | Skyclarys | $141 | 1 payment
|
See the published payment
| Biogen | Meals · 2025-10-31 | Skyclarys | $141 |
See earlier years (2024, 2023, 2022, 2019)
2024: $191
| GlaxoSmithKline | None | $115 | 1 payment
|
| Olympus Corporation of the Americas | Single Use Suction Valve (Sterile) | $76 | 3 payments
|
2023: $222
| GlaxoSmithKline | None | $222 | 2 payments
|
2022: $45
| Harmony Biosciences | Wakix | $45 | 1 payment
|
2019: $125
| Gilead Sciences | Vemlidy | $125 | 1 payment
|
Professional record
- NPI
- 1871722298
- Licence
- CA NA/PENDING 2010
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 710 Lawrence Expy, Gme Department #384, Santa Clara, CA, 95051
- NPI first listed
- 2009-07-07
- NPI last updated
- 2021-12-15
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.